Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas. (Q44193651)

From Wikidata

Jump to navigation Jump to search

scientific article published on 12 February 2013

Language	Label	Description	Also known as
English	Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas.	scientific article published on 12 February 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23400679%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23400679%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23400679%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Alexandre Harlé

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23400679%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Marie Rouyer

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23400679%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Valentin Harter

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23400679%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Pascal Genin

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23400679%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Agnès Leroux

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23400679%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Jean-Louis Merlin

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23400679%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

publication date

12 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23400679%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Virchows Archiv

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23400679%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

462

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23400679%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23400679%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

329-335

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23400679%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

https://scigraph.springernature.com/pub.10.1007/s00428-013-1380-x

0 references

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1380-X

21 January 2018

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1380-X

21 January 2018

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1380-X

21 January 2018

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1380-X

21 January 2018

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1380-X

21 January 2018

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1380-X

21 January 2018

The use of real-time PCR methods in DNA sequence variation analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1380-X

21 January 2018

High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1380-X

21 January 2018

Comparison of KRAS mutation tests in colorectal cancer patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1380-X

21 January 2018

The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: a comparison between direct sequencing and real-time PCR.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1380-X

21 January 2018

Setting future standards for KRAS testing in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1380-X

21 January 2018

Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1380-X

21 January 2018

Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1380-X

21 January 2018

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1380-X

21 January 2018

Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1380-X

21 January 2018

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1380-X

21 January 2018

External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1380-X

21 January 2018

Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1380-X

21 January 2018

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1380-X

21 January 2018

Biological and biochemical properties of human rasH genes mutated at codon 61.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1380-X

21 January 2018

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1380-X

21 January 2018

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1380-X

21 January 2018

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/23400679

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

1 reference

https://pubmed.ncbi.nlm.nih.gov/23400679

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23400679

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ask the Experts: NICE guidance on the diagnosis and treatment of colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23400679

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/23400679

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations

1 reference

https://pubmed.ncbi.nlm.nih.gov/23400679

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23400679

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00428-013-1380-X

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23400679%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23400679%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44193651&oldid=2108399243"